Acute myeloid leukemia and myelodysplastic syndromes in older adults

Journal of Clinical Oncology

Volumn 32, Issue 24, 2014, Pages 2541-2552

  Klepin, Heidi D ^a   Rao, Arati V ^b   Pardee, Timothy S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; DNA METHYLTRANSFERASE INHIBITOR; GEMTUZUMAB; GEMTUZUMAB OZOGAMICIN; GROWTH FACTOR; IMMUNOMODULATING AGENT; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT DISEASE; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COMORBIDITY; CYTOGENETICS; DNA METHYLATION; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INDUCTION CHEMOTHERAPY; INTENSIVE CARE; LIFE EXPECTANCY; MEMBRANE BIOLOGY; MORBIDITY; MYELODYSPLASTIC SYNDROME; PATIENT ASSESSMENT; PATIENT CARE; PATIENT RISK; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE TRANSFUSION; AGE; AGED; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES;

EID: 84906257606     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.1564     Document Type: Article

References (95)

1. Surveillance, Epidemiology, and End Results program: SEER Cancer Statistics Review 1975-2009. http://seer.cancer.gov/archive/csr/1975-2009- pops09/
2. Juliusson G: Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment. Blood 117:3473-3474, 2011
3. Kantarjian H, Ravandi F, O'Brien S, et al: Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116:4422-4429, 2010
4. Juliusson G, Antunovic P, Derolf A, et al: Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113:4179-4187, 2009
5. Oran B, Weisdorf DJ: Survival for older patients with acute myeloid leukemia: A population-based study. Haematologica 97:1916-1924, 2012
6. Wetzler M, Mrózek K, Kohlschmidt J, et al: Intensive induction is effective in select octogenarian acute myeloid leukemia patients: Prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica 99:308-313, 2014
7. Löwenberg B, Zittoun R, Kerkhofs H, et al: On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7:1268-1274, 1989 (Pubitemid 19220128)
8. Shah A, Andersson TM, Rachet B, et al: Survival and cure of acute myeloid leukaemia in England, 1971-2006: A population-based study. Br J Haematol 162:509-516, 2013
9. Thein MS, Ershler WB, Jemal A, et al: Outcome of older patients with acute myeloid leukemia: An analysis of SEER data over 3 decades. Cancer 119:2720-2727, 2013
10. Appelbaum FR, Gundacker H, Head DR, et al: Age and acute myeloid leukemia. Blood 107:3481-3485, 2006
11. Kamminga LM, de Haan G: Cellular memory and hematopoietic stem cell aging. Stem Cells 24: 1143-1149, 2006 (Pubitemid 44464682)
12. Liang Y, Van Zant G, Szilvassy SJ: Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood 106: 1479-1487, 2005 (Pubitemid 41129619)
13. Rossi DJ, Bryder D, Zahn JM, et al: Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A 102:9194-9199, 2005 (Pubitemid 40923540)
14. Plesa C, Chelghoum Y, Plesa A, et al: Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: A singleinstitution experience. Cancer 112:572-580, 2008 (Pubitemid 351192915)
15. Farag SS, Archer KJ, Mrózek K, et al: Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood 108:63-73, 2006 (Pubitemid 43996625)
16. Grimwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98:1312-1320, 2001
17. Rao AV, Valk PJ, Metzeler KH, et al: Agespecific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 27:5580-5586, 2009
18. Scholl S, Theuer C, Scheble V, et al: Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Eur J Haematol 80: 208-215, 2008 (Pubitemid 351253464)
19. Garrido SM, Cooper JJ, Appelbaum FR, et al: Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and druginduced apoptosis. Leuk Res 25:23-32, 2001 (Pubitemid 32012978)
20. Leith CP, Kopecky KJ, Chen IM, et al: Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group study. Blood 94:1086-1099, 1999 (Pubitemid 29361842)
21. Smyth MJ, Krasovskis E, Sutton VR, et al: The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A 95:7024-7029, 1998
22. Nipp RD, Rao AV: Performance status in elderly patients with acute myeloid leukemia: Exploring gene expression signatures of cytokines and chemokines. J Gerontol A Biol Sci Med Sci [epub ahead of print on June 19, 2013]
23. Marcucci G, Yan P, Maharry K, et al: Epigenetics meets genetics in acute myeloid leukemia: Clinical impact of a novel seven-gene score. J Clin Oncol 32:548-556, 2014
24. Mrózek K, Marcucci G, Nicolet D, et al: Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 30:4515-4523, 2012
25. Kantarjian H, O'Brien S, Cortes J, et al: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer 106:1090-1098, 2006
26. Tilly H, Castaigne S, Bordessoule D, et al: Lowdose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8:272-279, 1990 (Pubitemid 20056558)
27. Löwenberg B, Suciu S, Archimbaud E, et al: Mitoxantrone versus daunorubicin in induction consolidation chemotherapy: The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly-Final report: European Organisation for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 16:872-881, 1998 (Pubitemid 28115455)
28. Goldstone AH, Burnett AK, Wheatley K, et al: Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 98:1302-1311, 2001
29. Pautas C, Merabet F, Thomas X, et al: Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: Results of the ALFA-9801 study. J Clin Oncol 28:808-814, 2010
30. Serve H, Krug U, Wagner R, et al: Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: Results from a randomized, placebo-controlled trial. J Clin Oncol 31:3110-3118, 2013
31. Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia: Cancer and Leukemia Group B. N Engl J Med 332:1671-1677, 1995
32. Baer MR, George SL, Dodge RK, et al: Phase 3 study of the multidrug resistance modulator PSC- 833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100:1224-1232, 2002 (Pubitemid 34864276)
33. Löwenberg B, Ossenkoppele GJ, van Putten W, et al: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361: 1235-1248, 2009
34. Castaigne S, Pautas C, Térre C, et al: Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA- 0701): A randomised, open-label, phase 3 study. Lancet 379:1508-1516, 2012
35. Burnett AK, Russell NH, Hills RK, et al: Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 30:3924-3931, 2012
36. Kantarjian HM, Thomas XG, Dmoszynska A, et al: Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670-2677, 2012
37. Burnett AK, Milligan D, Prentice AG, et al: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114-1124, 2007 (Pubitemid 46435390)
38. Burnett AK, Russell NH, Hunter AE, et al: Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 122:1384-1394, 2013
39. Burnett AK, Russell NH, Culligan D, et al: The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br J Haematol 158:519-522, 2012
40. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562-569, 2010
41. Cassileth PA, Harrington DP, Hines JD, et al: Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 6:583-587, 1988
42. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med 331:896-903, 1994 (Pubitemid 24299870)
43. Hassanein M, Atenafu EG, Schuh AC, et al: High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission. Leuk Res 37:556-560, 2013
44. Stone RM, Berg DT, George SL, et al: Postremission therapy in older patients with de novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98:548-553, 2001
45. Hahn T, McCarthy PL Jr, Hassebroek A, et al: Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 31:2437-2449, 2013
46. McClune BL, Weisdorf DJ, Pedersen TL, et al: Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 28:1878-1887, 2010
47. Farag SS, Maharry K, Zhang MJ, et al: Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 17: 1796-1803, 2011
48. Krug U, Röllig C, Koschmieder A, et al: Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: A Web-based application for prediction of outcomes. Lancet 376:2000-2008, 2010
49. Röllig C, Thiede C, Gramatzki M, et al: A novel prognostic model in elderly patients with acute myeloid leukemia: Results of 909 patients entered into the prospective AML96 trial. Blood 116:971-978, 2010
50. Wheatley K, Brookes CL, Howman AJ, et al: Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 145:598-605, 2009
51. Deschler B, Ihorst G, Platzbecker U, et al: Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 98: 208-216, 2013
52. Klepin HD, Geiger AM, Tooze JA, et al: Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 121:4287-4294, 2013
53. Sherman AE, Motyckova G, Fega KR, et al: Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes. Leuk Res 37:998-1003, 2013
54. Etienne A, Esterni B, Charbonnier A, et al: Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 109:1376-1383, 2007 (Pubitemid 46466565)
55. Giles FJ, Borthakur G, Ravandi F, et al: The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136:624-627, 2007 (Pubitemid 46148199)
56. Djunic I, Virijevic M, Novkovic A, et al: Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia. Hematology 17:53-58, 2012
57. Savic A, Kvrgic V, Rajic N, et al: The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients. Leuk Res 36:479-482, 2012
58. Breccia M, Frustaci AM, Cannella L, et al: Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol 27:148-153, 2009
59. Wedding U, Röhrig B, Klippstein A, et al: Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol 132:665-671, 2006 (Pubitemid 44310332)
60. Klepin HD, Geiger AM, Tooze JA, et al: The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc 59:1837-1846, 2011
61. Alibhai SM, O'Neill S, Fisher-Schlombs K, et al: A clinical trial of supervised exercise for adult inpatients with acute myeloid leukemia (AML) undergoing induction chemotherapy. Leuk Res 36: 1255-1261, 2012
62. Klepin HD, Danhauer SC, Tooze JA, et al: Exercise for older adult inpatients with acute myelogenous leukemia: A pilot study. J Geriatr Oncol 2:11-17, 2011
63. Mohamedali H, Breunis H, Timilshina N, et al: Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia. Leuk Res 36:1241-1248, 2012
64. Rollison DE, Howlader N, Smith MT, et al: Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112:45-52, 2008
65. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997 (Pubitemid 27132124)
66. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007 (Pubitemid 47315575)
67. Greenberg PL, Tuechler H, Schanz J, et al: Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454-2465, 2012
68. Voso MT, Fenu S, Latagliata R, et al: Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol 31:2671-2677, 2013
69. Mishra A, Corrales-Yepez M, Ali NA, et al: Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol 88:566-570, 2013
70. Della Porta MG, Malcovati L, Strupp C, et al: Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 96:441-449, 2011
71. Naqvi K, Garcia-Manero G, Sardesai S, et al: Association of comorbidities with overall survival in myelodysplastic syndrome: Development of a prognostic model. J Clin Oncol 29:2240-2246, 2011
72. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429-2440, 2002 (Pubitemid 34525728)
73. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10:223-232, 2009
74. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803, 2006
75. Kantarjian H, Oki Y, Garcia-Manero G, et al: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57, 2007 (Pubitemid 46053042)
76. Fenaux P, Giagounidis A, Selleslag D, et al: A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118:3765-3776, 2011
77. Moyo V, Lefebvre P, Duh MS, et al: Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: A metaanalysis. Ann Hematol 87:527-536, 2008
78. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al: A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 120:1037-1046, 2003 (Pubitemid 36411563)
79. Park S, Grabar S, Kelaidi C, et al: Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. Blood 111:574-582, 2008
80. Jädersten M, Malcovati L, Dybedal I, et al: Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 26:3607-3613, 2008
81. Greenberg PL, Attar E, Bennett JM, et al: Myelodysplastic syndromes: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 11:838-874, 2013
82. Jädersten M, Montgomery SM, Dybedal I, et al: Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 106:803-811, 2005 (Pubitemid 41076418)
83. Kornblith AB, Herndon JE 2nd, Silverman LR, et al: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study. J Clin Oncol 20:2441-2452, 2002 (Pubitemid 34525729)
84. Seymour JF, Fenaux P, Silverman LR, et al: Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 76:218-227, 2010
85. Itzykson R, Thépot S, Quesnel B, et al: Longterm outcome of higher-risk MDS patients treated with azacitidine: An update of the GFM compassionate program cohort. Blood 119:6172-6173, 2012
86. Wang R, Gross CP, Frick K, et al: The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leuk Res 36:1370-1375, 2012
87. Xicoy B, Jiménez MJ, García O, et al: Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. Leuk Lymphoma [epub ahead of print on September 16, 2013]
88. List A, Dewald G, Bennett J, et al: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465, 2006 (Pubitemid 44511560)
89. Revicki DA, Brandenburg NA, Muus P, et al: Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: Results from a randomized clinical trial. Leuk Res 37:259-265, 2013
90. Zeidan AM, Gore SD, McNally DL, et al: Lenalidomide performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer 119: 3870-3878, 2013
91. Adès L, Boehrer S, Prebet T, et al: Efficacy and safety of lenalidomide in intermediate-2 or highrisk myelodysplastic syndromes with 5q deletion: Results of a phase 2 study. Blood 113:3947-3952, 2009
92. Sibon D, Cannas G, Baracco F, et al: Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Br J Haematol 156:619-625, 2012
93. Brunner AM, Kim HT, Coughlin E, et al: Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 19:1374-1380, 2013
94. Estey E, de Lima M, Tibes R, et al: Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109:1395-1400, 2007 (Pubitemid 46239569)
95. Koreth J, Pidala J, Perez WS, et al: Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: An international collaborative decision analysis. J Clin Oncol 31:2662-2670, 2013